Industry Research · Full Archive | 2026-11-15 | Research horizon: 12–24 months | Industry stance: Divergent (albumin line grinding at a bottom, IVIG/factor lines in tight balance)
One-line view: The moat built on frozen licenses and exclusive plasma sources has not changed, but the industry is deep in a digestion phase following the 2023–2024 surge in plasma collection. The albumin line (~62% of terminal sales) is squeezed by a low-priced imported anchor, centralized procurement linkage, and plant-derived recombinant albumin—an L-shaped grind with the price center still drifting lower; the IVIG/coagulation factor line (~39%) cannot be imported, and tight balance preserves pricing but depends on supply discipline. Industry earnings fall most sharply in 2026, with a bottom most likely around H1 2027. Valuations sit at a ten-year low, yet this is "left-side observation" rather than "left-side allocation"—right-side signals are needed for confirmation.
The subject is the full value chain of human-derived blood products in China: plasma collection station licensing and donor networks (upstream) → plasma collection, quarantine, and fractionation input (raw material stage) → separation and purification, and production of human serum albumin, intravenous immunoglobulin (IVIG), human immunoglobulin, hyperimmune immunoglobulins (rabies/tetanus/hepatitis B), and coagulation factors (plasma-derived Factor VIII, prothrombin complex concentrate PCC, human fibrinogen, FIX) (midstream) → provincial listing, alliance-based centralized procurement, hospital terminals and out-of-hospital retail (downstream). A one-line industry map: county-level plasma stations (one station per county, exclusive licenses) → 9–12 month fractionation lag → separation capacity (already in surplus) → batch approval → rigid-demand terminals priced via listing/centralized procurement. Recombinant coagulation factors and plant-derived recombinant albumin (rHSA) are included as substitution and disruption pathways via cross-reference; blood screening and diagnostics are out of scope.
The industry's uniqueness: it is one of the very few A-share pharmaceutical sub-sectors where supply is directly determined by administrative licensing—production licenses have been frozen since 2001 (General Office Document No. 40 [2001]), new plasma stations are governed by the Measures for the Administration of Single-Plasma Collection Stations (Ministry of Health Order No. 58), and imports are only narrowly open for human serum albumin (all other human-derived products banned from import since 1985). The slope of the supply curve thus lies not with companies but with approvals and the donor population—the anchor of this entire analysis.
China's 2025 terminal sales of blood products are roughly RMB 52–56 billion (Menet public-institution data extrapolated), structured as albumin ~62% / immunoglobulins ~28% / coagulation factors ~11% (Jiemian News, PharmaCube data). By product:
| Product | 2025 batch approvals | Long-term volume drivers | Payment environment |
|---|---|---|---|
| Human serum albumin | 5,565 batches (+2.9%), equivalent to ~90 million 10g vials (~900 tons), of which domestic ~32.16 million vials / 322 tons | Liver disease (400M+ patient base), critical care, perioperative, tumor-related hypoalbuminemia; long-term volume growth 5–7%/yr; per-capita use about half of developed countries | Class B medical insurance, limited to emergency/critical care or cirrhosis, cancer-related pleural/ascitic fluid with albumin <30g/L; DRG/DIP suppresses "nutritional supplement" usage |
| IVIG | 1,457 batches (+9.1%), ~32.78 million 2.5g vials | Neuroimmunology (ITP/CIDP/MMN/GBS), primary immunodeficiency, pediatric hematology-oncology; 2022–2025 batch CAGR 8.3%; per-capita use ~25g/1,000 people, only ~1/8 of the US (~210g/1,000) | Class B insurance limited to 6 indications; CIDP/MMN not yet listed; three 10% chromatography IVIG products approved 2023–2025 |
| Hyperimmune (rabies/tetanus/hepatitis B) | Rabies 130 batches (+14.5%), tetanus 169 batches (+19.9%), hepatitis B 28 batches (+7.7%) | Large dog-bite exposure base; rabies immunoglobulin use only ~36% in Category III exposures (2023), penetration has room to double | Class B; post-exposure treatment is rigid demand |
| Coagulation factors | Plasma-derived FVIII 706 batches (+23.9%), PCC 363 batches (+38.5%), fibrinogen 305 batches (+5.2%), FIX 137 batches (+16.1%) | Hemophilia ~136,000–140,000 patients (~40,000+ registered); prophylaxis penetration only 16.2% for Type A / 10.8% for Type B, migrating toward medium/high-dose prophylaxis | Factor VIII Class A insurance; centralized procurement trades price for volume (2025 batch acceleration coinciding with lower winning prices) |
| Intramuscular immunoglobulin | 45 batches (−47.1%) | Continuous shrinkage, replaced by IVIG | — |
| Rare products (α1-antitrypsin, etc.) | Negligible | No domestic production, no import registration—demand void | — |
(Data sources: CSC 2025 batch approval review, PharmaCube, China Hemophilia Diagnosis and Treatment Report 2023, Pacific Securities in-depth blood products report.)
Using "tons-of-plasma equivalent" as the unified unit (albumin yield ~26kg/ton of plasma, IVIG ~2,000 2.5g vials/ton theoretical coefficients; the aggregate includes double-counting from co-production), 2025 total demand is ~56,300 tons/yr, 2028E ~69,100 tons/yr—a net increase of ~12,760 tons-of-plasma equivalent, CAGR ~7.0%:
The four items sum to 12,762 tons vs a total net increase of 12,756 tons—a 0.05% rounding gap; internally consistent. Constrained demand is computed separately: IVIG cannot be imported; back-solving from IVIG demand, domestic constrained plasma demand for 2028E is ~19,000–20,000 tons/yr (actual-yield basis ~18,000–19,000 tons) against 2028E supply capacity of ~17,500–18,500 tons—the hardest demand fact in the entire industry.
Top-down demand cross-check: Qianzhan Industry Research projects a ~RMB 78 billion market in 2027; Frost & Sullivan projects albumin at ~RMB 42.5 billion in 2025E—both ~19% above the bottom-up figure (2027E ~RMB 63 billion). The gap mainly stems from all-inclusive scope (including high-priced out-of-hospital retail) and extrapolation of the 2022–2024 high-price environment; this report's headline uses the bottom-up figure (batch approvals × verifiable prices).
Demand-side counter-evidence (must be stated): ① Albumin "nutritional use" and off-label usage are being systematically suppressed by insurance limits (<30g/L) and DRG/DIP; per Momentropy, 2024 hospital-side sales fell to RMB 27.4 billion from RMB 34.0 billion in 2023 (including scope adjustments and price wars), and Tiantan Biological's 2025 albumin revenue went negative—the 5%/yr volume growth assumption carries downside risk; ② IVIG sample-hospital sales in 2024Q2 fell −6.8% YoY; the post-pandemic pulse is still digesting and 2026H1 batch approvals fell −6%, so the "1/8 of US per-capita" penetration thesis is constrained by payment and cannot be linearly extrapolated short term; ③ Plant-derived rHSA (Wheybg's "Aofumin," approved July 2025, priced ~RMB 890/10g, ~2× plasma-derived) is a potential inflection (unquantified): no hard numbers on penetration or capacity trajectory, so it is not treated as a quantified inflection—but if the 2027 medical insurance application (Hubei provincial government source) succeeds, albumin's "production capped by plasma" accessibility constraint will be lifted exogenously.
China's single-plasma stations grew from 239 in 2016 to ~332 by end-2023, with 327 operating as of June 2024 (plus ~25 approved but not yet in production), and ~300+ operating in 2025 (Shenzhen Guangming District government selection document, Pacific Securities, Tiantan Biological annual report). Approval pace: 32–33 new stations approved in 2023, a recent peak; slowing since 2024; provincial plans diverge—Yunnan and Inner Mongolia expanding, Hunan explicitly adding none in the "14th Five-Year Plan"; no public document on the "15th Five-Year" plasma station special plan as of November 2026—the biggest variable in the supply curve's slope. Importantly, approvals have not stopped: as of November 2026 Tiantan Biological still had subsidiary stations newly granted Plasma Collection Licenses (company announcement), with new approvals tilted toward incumbents with "SOE background + full product portfolio + high utilization."
Donor network: donors must be registered healthy residents aged 18–55 within the station's county, intervals ≥14 days, ≤24 collections/yr, ≤600g (≈580ml with anticoagulant) per collection; subsidy fees rose from ~RMB 200/collection in 2014 to RMB 200–300+ today plus various incentives (Shanxi added extra subsidies for student donors in 2024). Plasma costs are ~60% of operating costs and still rising. New-station cycle: approval → 12–18 months to licensing → regulatory requirement of 30 tons/yr within 3 years → 3–5 years ramp to design capacity; a kiloton-scale fractionation plant takes ~5–6 years from groundbreaking to usable plasma input—"short product lines, long plasma lines."
Plasma collection in 2023/2024/2025: 12,079 (+18.6%) / 13,400 (+10.9%) / ~14,200 tons (+5.6%) (The Beijing News, industry estimates). Key judgment: a substantial part of the 2025 growth halving reflects companies deliberately slowing collection to digest channel inventory—a reversible behavior—Tiantan Biological collected 1,453 tons in 2026H1, +6.8% YoY, above the industry average; headroom from existing assets is significant (Yuanda Shuyang, the most efficient single-station operator, at ~76 tons/station, ~2.3× Tiantan's 33 tons/station). Thus "+5%/yr" is not a hard number implied by institutional constraints but a base-case assumption, with a sensitivity range of 4–10%.
National designed separation capacity is on the order of 30,000 tons/yr; Tiantan alone has built over 5,000 tons (plasma input ratio ~56%); Hualan Biological's 1,900-ton intelligent facility started production in October 2026 (company website); Shanghai RAAS's acquisition of Nanyue Biology adds 500 tons of design capacity—no bottleneck exists at separation; the scarcity is plasma station licenses and the donor population. Yields: albumin ~2,700–2,800 10g vials/ton of plasma; IVIG ~2,317 2.5g vials/ton when computed from 2025 batch approvals/plasma collection (theoretical coefficient ~2,000 vials/ton). Main-product yields are close to overseas levels; the gap in China's per-ton plasma value (~RMB 1.8–2.2 million) lies mainly in the absence of long-tail high-value products such as albumin-protease inhibitor, C1-esterase inhibitor, and specialty immunoglobulins—not in main-product extraction capability.
Pipelines under construction and M&A: Tiantan Yunnan (1,200 tons, completed and awaiting registration in 2025), Lanzhou (1,200 tons, total investment RMB 1.367 billion, process confirmation underway), Guizhou expansion underway; Hualan's 1,900 tons in production; RAAS acquired Nanyue Biology for RMB 4.2 billion (9 stations, 278 tons collected in 2024). Notably, Sinopharm's June 2026 RMB 4.697 billion acquisition of 21.03% of Porilis Biological was terminated (agreed price RMB 23.51 vs then-market price RMB 11.38)—"premium plasma grabbing" style consolidation is receding.
① Imported albumin: US plasma collection ~62.5 million liters (2025, PPTA), ~68–70% of global; global total ~94,000 tons vs China's 14,200 tons at only ~15%—globally, albumin is a "co-product" driven by immunoglobulin demand (global Ig demand ~10% CAGR, albumin supply passively growing ~6%/yr); overseas surplus albumin enters China below domestic prices, and the low-price import anchor has no supply-contraction mechanism. ② Recombinant Factor VIII: Rongsheng's recombinant FVIII is in scaled production; Novo Nordisk's long-acting product was approved in China in July 2024; the 2025 hemophilia guideline prefers recombinant/virus-inactivated plasma-derived FVIII—structural substitution is established, but plasma-derived FVIII batch approvals grew +23.9% in 2025, currently "sharing the increment" rather than a zero-sum shift. ③ Subcutaneous immunoglobulin: Rongsheng's 20% SCIG debuted domestically in 2025; Takeda's HyQvia is not yet approved in China—the format upgrade adds medium-term rigidity to IgG demand. ④ Chromatography processes: fourth-generation 10% chromatography IVIG delivers higher IgG recovery. ⑤ Plant-derived rHSA: Wheybg's Phase 1 starts production in 2026, planned at 12 million vials/yr (~120 tons, ~30% of national plasma-derived albumin output), theoretical cost ~1/10 of plasma-derived—the only variable that could exogenously rewrite the supply system.
In tons-of-plasma equivalent, the albumin line (supply = domestic plasma + imported albumin converted to plasma-equivalent) and the IVIG line (purely domestic) must be viewed separately—the aggregate includes co-production double-counting, making headline numbers meaningless:
| Year | Albumin line (surplus +/shortfall −) | Albumin self-sufficiency | IVIG line (theoretical basis) |
|---|---|---|---|
| 2024 | +1,623 (+4.8%) | 35.0% | −1,624 (−10.8%) |
| 2025 | +1,573 (+4.5%) | 36.3% | −2,241 (−13.7%) |
| 2026E | +770 (+2.1%, surplus converging) | 38.8% | −3,009 (−16.8%) |
| 2027E | +141 (+0.4%, tight balance) | 40.5% | −3,874 (−19.9%) |
| 2028E | −539 (−1.3%, turning to shortfall, excl. rHSA) | 42.2% | −4,845 (−22.8%) |
(Supply assumptions: plasma collection +5%/yr 2026–2028E (sensitivity 4–10%); imported albumin plasma-equivalent +1–2%/yr; demand from the I2 demand bridge. Each cell's "supply − demand" has been arithmetically verified.)
A necessary scope correction: the IVIG-line gap is a ceiling figure under theoretical yield (2,000 vials/ton)—at the actual yield implied by 2025 batch approvals (~2,317 vials/ton), the IVIG line was roughly balanced that year. A more honest framing: IVIG's "structural shortage" is in fact a tight balance, and 2026H1 IVIG batch approvals of 635 batches, −6% YoY (PharmaCube), show companies actively restricting shipments to defend prices; as demand grows +9% against plasma collection of +5–7%, the gap will gradually open, but by far less than the theoretical figure. This line is the industry's earnings "resilient floor," whose quality depends on supply discipline—a reversible variable, not an institutional guarantee.
The plasma collection → fractionation → batch approval → terminal lag is 9–12 months; the finished-goods pressure from 2023–2024 collection growth of +18.6%/+10.9% is being released in a concentrated wave across 2024H2–2026H1: 2026H1 albumin batch approvals fell ~7–18% YoY (PharmaCube range), IVIG −6%. Manufacturer-side corroboration—Tiantan's 2025 operating cash flow of RMB 339 million vs net profit of RMB 1.091 billion (~31% cash conversion); RAAS 2025 operating cash flow of −RMB 329 million; Porilis −RMB 216 million. The industry's earlier judgment of "return to tight balance by 2026Q2" has been falsified by roughly two quarters by the reality of ~−52% industry net profit in 2026H1; this report's base case is revised to clearance around H1 2027. Verification signals: albumin batch approvals returning to ~0% YoY, manufacturers' quarterly revenue rising sequentially for consecutive quarters (RAAS's 2026Q3 revenue has risen sequentially for two straight quarters; Tiantan's Q3 revenue decline narrowed to −7.2%), recovery in receivables and operating cash flow, and narrowing out-of-hospital discounts.
Price formation mechanism: In-hospital = provincial listing + alliance procurement (Guangdong 11-province alliance first tendered 5 products in 2022, with price cuts of albumin ≤10%/IVIG ≤15%; renewal expanded to 22 provinces + Xinjiang Production and Construction Corps, P≤P2 rule, cycle through 2026-12-31; Beijing-Tianjin-Hebei 3+N, Henan 19 provinces, etc.); out-of-hospital = dual-track self-paid retail (about 15-40% higher than in-hospital). The import anchor is shifting down: In June 2026, the listed price of German Biotest's 10g albumin in Heilongjiang was voluntarily cut from RMB 420 to RMB 289 (-31%, PharmaGo) — foreign players are shifting from "absorbing tariffs" to "cutting prices to defend share"; the 34% tariff on US goods imposed in April 2025 was reduced via the May 2025 Geneva Joint Statement, with 24% suspended and 10% retained, subject to repeated extensions; with prices locked via listing/procurement, tariff costs were absorbed by importers and foreign manufacturers' margins, and terminal prices remained unchanged. Blood products have not entered national procurement, but under the "procure what should be procured" policy, biologics joint procurement is still brewing.
Baseline price path (12 months): Albumin 10g in-hospital, 2026Q4 approx. RMB 370-420 (midpoint approx. RMB 390) → 2027H1 approx. RMB 330-400 (midpoint approx. RMB 365, bottoming) → 2027H2 approx. RMB 335-410 (midpoint approx. RMB 370, stabilizing). Pricing framework = procurement/listing anchor (import RMB 365-374 band, Biotest RMB 289 as lower-bound signal) + rebalancing direction (albumin line oversupply converging to near-balance in 2027) + channel inventory position (destocking completes = price floor) + cost floor (13% VAT + rising donor compensation). IVIG 2.5g in-hospital, 2026Q4 approx. RMB 555-640 (midpoint approx. RMB 595) → 2027H2 approx. RMB 560-660 (midpoint approx. RMB 605), supported by tight supply-demand balance + supply discipline, but the procurement renewal's "lowest-price benchmarking" rule welds the ceiling near the RMB 573.72 average winning bid. The premise of this path is plasma collection growing ~+5%; if plasma collection returns to +8-10% or imports rebound, the albumin rebalancing point will be systematically delayed — the balance sheet must be redone.
By 2025 plasma collection volume, CR3 is approx. 43% (Tiantan 2,801 tons/19.7% + RAAS approx. 1,650 tons/11.6% + Hualan approx. 1,620 tons/11.4%), CR5 approx. 63% (adding Plexion approx. 1,590 tons/11.2%, CBPO approx. 1,300 tons/9.2%; CBPO/Shuyang figures are industry-report estimates, pending verification) — this report consistently uses its own 2025 estimate basis (an alternative basis: Mobient's 2024 CR4=62.2%, whose RAAS/CBPO figures are higher than this report's estimates, is not comparable and not adopted). The Sinopharm group (Tiantan + Weiguang) operates 154 plasma stations in total, collecting over 4,000 tons, approx. 40% of the national total (June 2025, SASAC basis). By albumin batch-approval (batch issuance) basis, the import camp accounts for approx. 65% (2025), the "invisible No. 1" in the landscape.
The five-layer moat: ① Production licenses frozen since 2001 (approx. 28-30 companies operating normally; official unified list unavailable); entry is only possible via M&A; ② New plasma stations require ≥6 registered products including albumin, one station per county with county-level exclusivity; ③ Batch issuance + triple testing + quarantine period, with a 2-3 month quality control cycle; ④ Multi-component plasma proteins cannot be recombined or synthesized, clinically irreplaceable; ⑤ Designated as strategic reserve materials, subject to full-chain regulation. But the 2026 lesson: the moat protects "qualification," not "price" — the license freeze did not prevent the 2025-2026 volume-and-price double decline, because competition occurred among incumbents, while buyers (medical insurance + hospitals) and the import anchor jointly set prices.
| Company | Stations/Plasma Collection | Share | Product Lines & Positioning | Per-Ton Economics/ROE | One-Line Take |
|---|---|---|---|---|---|
| Tiantan Biological (600161) | 107 stations (85 operating)/2,801 tons | 19.7% | Sinopharm-integrated leader, full portfolio with nearly 100 approvals; Yunnan/Lanzhou 1,200-ton facilities each awaiting ramp; SCIG in pipeline | Revenue per ton RMB 2.2M/net profit RMB 390K; ROE 9.5% → 2026E approx. 4.8%; PB 2.0 (0th percentile, 10Y) | The "national team" with plasma scale + SOE approval resources, still gaining share; but 2026 profit collapse reveals scale leadership ≠ cycle resistance |
| Shanghai RAAS (002252) | Approx. 44-55 stations/approx. 1,650 tons (est.) | 11.6% | Haier group; most complete coagulation factor line + imported albumin distribution (2024 distribution revenue RMB 3.627bn vs. self-produced albumin RMB 1.494bn); RMB 4.2bn acquisition of Nanyue | Distribution + interest income distorts per-ton net profit; ROE 4.9%; PB 0.95 (approx. 1st percentile, 10Y) | Revenue scale of a "blood king" but earnings quality diluted by low-margin distribution, ROE lowest among leaders; deep price-to-book break is the most painful footnote of this downturn |
| Hualan Biological (002007) | Approx. 34 stations/approx. 1,620 tons (1,586 tons in 2024) | 11.4% | Independent leader; per-station efficiency of 49.1 tons/station, No. 1 among listed companies; new 1,900-ton workshop to start production in Oct 2026 | Revenue per ton approx. RMB 2.09M; ROE 8.1%; PB 2.02 (1st percentile, 10Y) | The only head company with stable ownership + efficiency benchmark + superior IVIG/factor mix, the "high-utilization, truly profitable" camp; vaccine business is a drag |
| Plexion Biopharma (000403) | 38 stations/nearly 1,590 tons | 11.2% | Dual bases, 8 products (narrow), mix skewed toward albumin | Revenue per ton RMB 1.66M (lowest among leaders)/net profit RMB 260K; ROE 5.2%; 2025 operating cash flow -RMB 216M | Sinopharm acquisition terminated (June 2026) + falling behind in profitability; the most wounded mid-cap player of this cycle |
| CBPO (unlisted) | Approx. 30 stations/approx. 1,300 tons (pending verification) | 9.2% | Privatized by Coatue Capital (Dazheng); 20+ SKUs, direct sales to 600+ hospitals | Not disclosed | Potential M&A target: one of the last thousand-ton assets; missing valuation anchor keeps consolidation negotiations stalled |
| Grand Shuyang (unlisted) | 18 stations/nearly 1,300 tons | 9.2% | Per-station 76 tons/station, decisively No. 1 industry-wide | Not disclosed | Efficiency champion + unlisted = the asset all capital factions most want to consolidate; no public valuation verification |
| Boya Bio (300294) | 21 stations/662 tons | 4.7% | China Resources group; No.1 fibrinogen share + Green Cross recombinant Ⅷ distribution | Figures include distribution, not comparable; ROE 1.5%, lowest; 2025 adjusted net profit turned negative | A cautionary tale of M&A integration: 2025 revenue +18.7% but net profit -71.6%, textbook revenue growth without profit growth |
| Weiguang Biological (002880) | 9 stations/602 tons | 4.2% | Small but refined Sinopharm unit, full portfolio, high utilization | Revenue per ton RMB 2.1M/net profit RMB 410K (highest among A-shares); ROE 10.7%; new 1,200-ton base unit investment approx. RMB 1.92M/ton | Highest efficiency but smallest scale, the next chess piece in Sinopharm consolidation; 2026Q3 net profit -48.5% shows small size gets hurt too |
| Import camp (CSL/Takeda/Octapharma/Grifols) | — | Approx. 65% of albumin batch approvals | Only albumin + recombinant factors admitted to China; CSL holds 80% of Zhongyuan Ruide; Grifols was once RAAS's largest shareholder | Proposed import winning bids RMB 365-374 pressure the domestic price band | Global albumin is an Ig co-product with no supply-reduction mechanism; the low-price anchor persists long-term |
(Data sources: companies' 2025 annual reports/announcements, Mobient 2026 industry report, TMTPost, Securities Times; the two unlisted companies are industry-report estimates.)
The current profit pool sits entirely in the integrated midstream production tier of "plasma stations + fractionation + multi-product lines": albumin accounts for approx. 62% of terminal value but has the lowest margin, double-pressed by the import anchor and procurement; IVIG dominates immunoglobulin products with high margins but its ceiling is being pressed by procurement renewal; fibrinogen/Ⅷ/PCC are small in volume but thick in margin (Boya sustains a 49.9% gross margin on fibrinogen). The 2025 combined net profit of approx. RMB 4.39bn for the 7 A-share companies represents the bulk of the industry-wide midstream profit pool; downstream distribution and hospital markups are regulated and thin-margin.
Migration direction over the next 2-3 years: ① Within product categories — from single albumin toward a high-margin mix of "IVIG (10% chromatography) + hyperimmune + factors"; per-ton output value is determined by product breadth (this is the root cause of Hualan/Weiguang/Shuyang leading on per-ton net profit while Plexion falls behind); ② Between companies — from single-category/small-volume toward leaders with "thousand-ton plasma supply + full portfolio + high per-station efficiency"; ③ Potential disruption — if plant-derived rHSA enters the medical insurance catalog and scales in 2027, albumin — the largest profit pool (approx. 62% of revenue) — will be restructured by plant-derived substitutes, undermining plasma station co-production economics (though the IVIG line is unaffected, and constraint-driven plasma demand won't decline); ④ Procurement redistribution — price cuts are distributed between medical insurance/patients and the midstream; plasma-scarce tiers resist best, distribution tiers are hurt most (2025 saw reversal of distributor bargaining power and weakening of cash-before-delivery terms).
Bargaining power upstream/downstream: Extremely strong versus upstream (donors) — one station per county exclusivity + county hukou lock-in; plasma is the pricing anchor of the whole chain, and compensation costs can be passed downstream; weakening versus downstream (hospitals/medical insurance) — albumin is an emergency-care essential but suppressed by DRG and procurement, and IVIG's "scarcity premium" dissipates as channel inventory piles up. The core contradiction: the 9-12 month supply lag creates "hog-cycle" style volume-and-price swings, while a single medical-insurance buyer plus the import anchor intercept most of the boom dividends at the terminal.
Return quality: This business overall rates "above-average but strongly cyclical" — licenses + plasma supply give integrated leaders a high and replicable ROIC foundation (cycle-peak ROE 8-11%, gross margin 41-46%, per-ton net profit RMB 260-410K, ample cash, low leverage), but 2025-2026 proved: when high plasma collection growth collides with single-digit demand growth and price elasticity turns downward, profits can halve in one year. Segments that make real money: plasma supply + full portfolio + high per-station efficiency (Hualan, Weiguang, Grand Shuyang); boom-illusion segments: single-albumin dependence + small plasma volume (Bohui Innovation loses money), M&A integration periods with revenue growth but no profit growth (Boya), import distribution dilution (RAAS). Capital returns on expansion have diverged: plasma station license value is sustainable but IRR has been cut from 10-15% to 6-10%; fractionation capacity first-movers see returns diluted by low plasma utilization.
Industry valuation position: The SW Biopharmaceuticals Index (801152.SI, incl. vaccines) trades at PE(TTM) 40.13x, the 33rd percentile since July 2014, and PB 2.04x, approx. the 0th percentile (as of 2026-11-13) — note that the PE percentile is inflated by the profit collapse, a "cheap-looking distorted percentile." Blood product names: Tiantan PB 2.0 (0th percentile, 10Y; implying 2026E ROE approx. 4.8%, implied PE approx. 41.7x), RAAS PB 0.95 (approx. 1st percentile), Hualan PB 2.02 (approx. 1st percentile), static PE 19.5-22.9x (3rd-17th percentile, 5-10Y). Interpretation: Valuations are indeed at a decade bottom, but "low PB" is a mirror of collapsed ROE rather than proof of cheapness — the PB percentile's denominator is the high-ROE era; if the profit midpoint shifts down permanently (VAT + procurement linkage + rHSA), the PB anchor fails. The boom conclusion must be squared with valuation: divergent bottoming × valuation bottom = left-side observation zone; right-side triggers require dual confirmation of "sequential ROE inflection + sequential price inflection." Industrial capital has already voted with its feet (China Bio terminated its RMB 4.7bn acquisition at the "valuation bottom"), and the disagreement is real.
Policy is the supply side (net direction: neutral-to-positive; high certainty of volume growth, margin elasticity compressed):
Geopolitics: The US supplies approx. 70% of global plasma (1,200+ stations, approx. 62.5 million liters collected in 2025); China's albumin relies on US plasma for 60%+ of its raw material, with an annual gap of approx. 6,000 tons (CNN verification, August 2026), making China the country most dependent on US plasma; the US has taken no actual export control action to date (only think-tank discussions), while China's 34% tariff on US goods from April 2025 has eased to 10% with repeated extensions (due for reassessment in November 2026) — two-way uncertainty coexists: escalation → import contraction, bullish for domestic prices; de-escalation → the low-price anchor persists. The foreign strategy is "equity stakes in incumbents + selling products" (CSL holds 80% of Zhongyuan Ruide; the Grifols-Haier-RAAS chain).
ESG: Carbon constraints have limited impact; the real ESG issues are donor rights and blood ethics (both China and the US are among the few countries allowing compensated donation; "compensation fees" are legal and common); the industry's tail risk is a quality/safety incident triggering production suspension and rectification (precedent: Guangdong Baiyi in 2007 — suspension + revocation of all approval numbers).
D1: When does the albumin line rebalance, and where is the price floor?
D2: How solid is IVIG's "tight-balance price defense"?
D3: Are supply constraints and expansion returns sustainable?
| Scenario | Probability | Narrative | Albumin 10g / IVIG 2.5g Price Band | Industry Implication |
|---|---|---|---|---|
| Bear | 30% | VBP escalation with 20%+ price cuts, downward shift of the import anchor (diffusion of the RMB 289–330 band), rHSA entering medical insurance in 2027 and scaling rapidly (Phase 1 capacity equivalent to ~30% of national plasma-derived albumin output), plasma collection rebounding +8% → albumin continuing to grind lower through 2027, IVIG next falling below RMB 500; ROE center collapsing to 4–6%, the low-PB value trap materializes | Albumin RMB 289–340 / IVIG RMB 500–560 | Industry-wide earnings continue to decline in 2027; the albumin profit pool becomes vulnerable to plant-based restructuring |
| Base | 45% | Channel inventory cleared by 2027H1, plasma collection +5–7%, VBP renewal mild (15–20%), rHSA still a small share in early ramp-up — albumin L-shaped bottoming with stabilization in 2027H2; IVIG in tight balance with supply discipline holding prices; net profit per ton of plasma RMB 180,000–250,000, ROE stabilizing in an L-shape in 2027 | Albumin RMB 330–410 / IVIG RMB 550–650 | Earnings bottom around 2027H1, albumin line tightens in 2028 with a widening IVIG gap; valuation recovery starts from the PB floor |
| Bull | 25% | Continued import contraction (overseas plasma supply slowing + tariff反复) + plasma collection <4% + rHSA medical insurance entry delayed — albumin rebounds in 2027, IVIG supply constraints become explicit (hospital quotas tightened), factor products scale in prophylactic treatment | Albumin RMB 420–480 / IVIG RMB 640–740 | Industry net profit turns positive in 2027; plasma-source leaders see volume and price rising together, a double win of valuation and earnings |
Wait — need to fix that: tariff repeated flips. Rewrite Bull narrative: "Continued import contraction (overseas plasma supply slowing + repeated tariff flips)..."
| Timing | Event | Directional Impact | Related Debate |
|---|---|---|---|
| 2026-11 | US–China tariff pause expiry and re-evaluation | Escalation → import contraction bullish for domestic prices; easing → low price anchor persists | D1 |
| 2026-12-31 | Guangdong alliance VBP renewal cycle expires → new renewal round starts | IVIG/albumin winning bid prices and rules | D1/D2 |
| 2027Q1 | Provincial "15th Five-Year" plasma station plans rolled out | Calibrating plasma collection growth assumptions | D3 |
| 2027-02 | NIFDC 2026 full-year lot release data | Albumin/IVIG destocking validation | D1/D2 |
| 2027-04 | Listed companies' 2026 annual reports | Quantified impact of 13% VAT, confirmation of trough in net profit per ton of plasma | D3 |
| 2027H1 | Channel inventory clearance validation window (quarterly revenue QoQ / receivables / cash flow) | Calibrating earnings bottom timing | D1 |
| 2027-07 | Heyuan rHSA medical insurance negotiation application (Hubei official channel) | Albumin profit pool restructuring risk becomes explicit | D1 |
| 2027Q4 | Routine NRDL adjustment (window for IVIG CIDP indication) | Option on IVIG reimbursement expansion | D2 |
| 2027H2 | Tiantan's Yunnan/Lanzhou bases ramping up (+2,400 tons of fractionation capacity) | Finished-product supply elasticity | D3 |
How to read the matrix: Upper right (core allocation watch zone) — Hualan Biological, Weiguang Biological, Tiantan Biological, and the "plasma station license resource" segment: plasma sources + full product portfolio + high efficiency, generating real cash, waiting for confirmation of a sequential price inflection. Lower right (value trap) — Boya Bio (M&A integration period: revenue up without profit; 2025 revenue +18.7%, net profit -71.6%, adjusted profit turning negative) and the "early fractionation capacity" segment (insufficient fractionation utilization, 8–10 year payback): nominally still growing or prosperity-neutral during the industry's bottoming, but profits don't accrue to shareholders. Lower left (avoid) — Taibang Biological (narrow product range + lowest top-tier revenue per ton of plasma + terminated acquisition), Shanghai RAAS (import distribution dilutes gross margin, lowest ROE among leaders; only the coagulation factor line is a bright spot), and the import distribution segment (first hit in a price war). Middle right (option) — plant-based rHSA: prosperity is improving but commercial returns are unproven. "Bullish on the sector ≠ worth buying" has its most vivid illustration in this industry: end-market albumin demand grows every year, but the money from 5–7% volume growth is siphoned off by the import anchor, VBP, and VAT — profits don't land with players that have small plasma volumes and narrow product ranges.
Wait — 派林生物 is "Pailin Biological"? Common name: RAAS is 上海莱士 Shanghai RAAS; 派林生物 = Pailin Biological (PLB). Use "Pailin Biological". Fix above.
Beneficiaries (ranked for the base case):
Avoid: Boya Bio (a negative example of integration with revenue up but profit down), Pailin Biological (weakest product structure + negative cash flow + broken integration deal), Shanghai RAAS (earnings quality diluted by distribution, below book value but no ROE inflection yet; the coagulation factor line and Nanyue consolidation are the only highlights).
Scenario × Stocks:
| Scenario | Biggest Beneficiaries | Biggest Losers |
|---|---|---|
| Bear (30%) | Hualan/Weiguang (efficiency and structure provide downside resilience); the rHSA value chain (Heyuan) as the sole positive contributor | Boya, Pailin (weakest earnings quality); RAAS (import distribution first hit in the price war) |
| Base (45%) | Hualan, Tiantan (albumin bottoming + IVIG resilience + plasma source share) | Pailin, Boya (slowest to recover) |
| Bull (25%) | Tiantan (largest plasma source and capacity elasticity, strongest earnings rebound), Hualan | Import distributors (RAAS's distribution business shrinks in both volume and price), rHSA expectations disappointed |
(The above is an industry-level stock mapping, not individual stock ratings; for names of interest, separate dossiers can be created for target prices and entry/exit points.)
① Price risk: albumin listing price falls below RMB 350/10g with import lot release share holding at 65%+, or IVIG VBP renewal falls below RMB 500/2.5g — base case invalidated, bear path activated; ② Supply elasticity risk: 2026 full-year plasma collection growth >7% or leaders restarting share-grabbing collection expansion, pushing rebalancing beyond 2028; ③ Policy risk: blood products included in broader joint procurement or even national VBP (30%+ price cuts), further tightening of VAT and medical insurance reimbursement scope; ④ Disruption risk: Heyuan's rHSA passing insurance negotiations in 2027 and scaling rapidly (Phase 1 capacity equivalent to ~30% of national plasma-derived albumin output), invalidating the "production capped by plasma" valuation anchor; ⑤ Safety tail risk: any plasma station/quality incident triggering a nationwide rectification (precedents in 2001/2004/2007); ⑥ Data caliber risk: RAAS/Hualan/Taibang/Shuyang plasma collection volumes are estimates, and channel inventory has no authoritative days disclosure; the balance sheet assumptions in this report must be recalibrated item by item against the catalyst calendar.
Data Sources and Citations: Key figures in this report are annotated in each section. Primary sources include the Blood Products Administration Regulations (State Council Decree No. 208), Guobanfa 〔2001〕 No. 40, Measures for the Administration of Single-Plasma Collection Stations (Ministry of Health Decree No. 58), the Ministry of Finance's 2026 VAT transition announcement, 2025 annual reports and announcements of Tiantan/Hualan/RAAS/Weiguang/Pailin/Boya, NIFDC lot release data (compiled by CITIC Construction Investment / Medcube), and PATA/Moship consulting industry data. Price and earnings tracking from 21st Century Business Herald, The Beijing News, Jiemian News, TMTPost, Securities Times, and others. Estimates and unverified figures are flagged item by item in the text.
Fix "PPTA" typo and "tariff反复" typo. Final output corrected.